FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Share this entry
- American Health Council Elects Billie Anderson, MSN/APRN to Nursing Board September 15, 2017
- American Health Council Names April Francis, BS, ITIL to Industry Board September 14, 2017
- Dawn Howard-Mistry, MSN, BSN, APN-C, is Elected to the American Health Council’s Board of Nurses September 12, 2017
- AHC Provide’s Leadership & Involvement Opportunities September 12, 2017
- The American Health Council Welcomes Claire Byrd, MSN, ARNP, FNP-C, CNRN, to its Board of Nurses September 11, 2017
- Dr. Christine Fall is Appointed to the American Health Council’s Board of Physicians September 8, 2017